OPK Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of 14.26% compared to OPKO Health, Inc.'s net margin of -12425.36%. OPKO Health, Inc.'s return on equity of -13.5% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

OPKO Health, Inc. has a consensus price target of $3.56, signalling upside risk potential of 169.57%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 354.16%. Given that Perspective Therapeutics, Inc. has higher upside potential than OPKO Health, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than OPKO Health, Inc..

OPKO Health, Inc. has a beta of 1.389, which suggesting that the stock is 38.889% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

OPKO Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OPKO Health, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

OPKO Health, Inc. quarterly revenues are $151.7M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. OPKO Health, Inc.'s net income of $21.6M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, OPKO Health, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OPKO Health, Inc. is 1.64x versus 183.75x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

OrthoPediatrics Corp. has a net margin of 14.26% compared to OPKO Health, Inc.'s net margin of -19.22%. OPKO Health, Inc.'s return on equity of -13.5% beat OrthoPediatrics Corp.'s return on equity of -12.83%.

OPKO Health, Inc. has a consensus price target of $3.56, signalling upside risk potential of 169.57%. On the other hand OrthoPediatrics Corp. has an analysts' consensus of $24.13 which suggests that it could grow by 33.21%. Given that OPKO Health, Inc. has higher upside potential than OrthoPediatrics Corp., analysts believe OPKO Health, Inc. is more attractive than OrthoPediatrics Corp..

OPKO Health, Inc. has a beta of 1.389, which suggesting that the stock is 38.889% more volatile than S&P 500. In comparison OrthoPediatrics Corp. has a beta of 1.091, suggesting its more volatile than the S&P 500 by 9.108%.

OPKO Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OrthoPediatrics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OPKO Health, Inc. pays -- of its earnings as a dividend. OrthoPediatrics Corp. pays out -- of its earnings as a dividend.

OPKO Health, Inc. quarterly revenues are $151.7M, which are larger than OrthoPediatrics Corp. quarterly revenues of $61.3M. OPKO Health, Inc.'s net income of $21.6M is higher than OrthoPediatrics Corp.'s net income of -$11.8M. Notably, OPKO Health, Inc.'s price-to-earnings ratio is -- while OrthoPediatrics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OPKO Health, Inc. is 1.64x versus 1.86x for OrthoPediatrics Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Solventum Corp. has a net margin of 14.26% compared to OPKO Health, Inc.'s net margin of 60.4%. OPKO Health, Inc.'s return on equity of -13.5% beat Solventum Corp.'s return on equity of 42.2%.

OPKO Health, Inc. has a consensus price target of $3.56, signalling upside risk potential of 169.57%. On the other hand Solventum Corp. has an analysts' consensus of $88.55 which suggests that it could grow by 12.21%. Given that OPKO Health, Inc. has higher upside potential than Solventum Corp., analysts believe OPKO Health, Inc. is more attractive than Solventum Corp..

OPKO Health, Inc. has a beta of 1.389, which suggesting that the stock is 38.889% more volatile than S&P 500. In comparison Solventum Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OPKO Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OPKO Health, Inc. pays -- of its earnings as a dividend. Solventum Corp. pays out -- of its earnings as a dividend.

OPKO Health, Inc. quarterly revenues are $151.7M, which are smaller than Solventum Corp. quarterly revenues of $2.1B. OPKO Health, Inc.'s net income of $21.6M is lower than Solventum Corp.'s net income of $1.3B. Notably, OPKO Health, Inc.'s price-to-earnings ratio is -- while Solventum Corp.'s PE ratio is 9.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OPKO Health, Inc. is 1.64x versus 1.64x for Solventum Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 14.26% compared to OPKO Health, Inc.'s net margin of 14.18%. OPKO Health, Inc.'s return on equity of -13.5% beat Stryker Corp.'s return on equity of 14.06%.

OPKO Health, Inc. has a consensus price target of $3.56, signalling upside risk potential of 169.57%. On the other hand Stryker Corp. has an analysts' consensus of $427.40 which suggests that it could grow by 20.38%. Given that OPKO Health, Inc. has higher upside potential than Stryker Corp., analysts believe OPKO Health, Inc. is more attractive than Stryker Corp..

OPKO Health, Inc. has a beta of 1.389, which suggesting that the stock is 38.889% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 10.974%.

OPKO Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.96% to investors and pays a quarterly dividend of $0.88 per share. OPKO Health, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

OPKO Health, Inc. quarterly revenues are $151.7M, which are smaller than Stryker Corp. quarterly revenues of $6.1B. OPKO Health, Inc.'s net income of $21.6M is lower than Stryker Corp.'s net income of $859M. Notably, OPKO Health, Inc.'s price-to-earnings ratio is -- while Stryker Corp.'s PE ratio is 46.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OPKO Health, Inc. is 1.64x versus 5.63x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.